

## **GVK BIO enters into research collaboration with Endo Pharmaceuticals**

GVK Biosciences (GVK BIO), Asia's leading drug discovery research and development CRO announced today that it has entered into a collaboration agreement with U.S. based Endo Pharmaceuticals focused on discovering novel small molecules targeting an exciting protein. Under this agreement GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product arising out of this collaboration. This collaboration arose out of a newly launched concept at GVK BIO named Early Discovery Assets (EDA™).

Manni Kantipudi, CEO of GVK BIO commented, *“We are delighted to partner with Endo as it continues to build its discovery pipeline through external collaborations. This collaboration also confirms the value of our differentiated EDA™ concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates.”*

Dr. Sandeep Gupta, Endo's Senior Vice President of Drug Discovery and Early Development stated *“We are pleased to initiate this discovery collaboration with GVK BIO. With their world class infrastructure and an experienced scientific team, I have no doubt that they will execute on the program goals and add to our portfolio of development candidates that provide novel treatment options for the patients”.*

### **EDA™ (Early Discovery Assets) A new discovery offering from GVK BIO**

GVK Biosciences, through its internal expertise in computational chemistry, discovery biology and medicinal chemistry, is building a portfolio of discovery project assets for potential early stage partnering. This early stage asset portfolio is focused around Pain and Inflammation. GVK Biosciences develops these assets to a stage of demonstrated value and then looks to partner and co-develop them with life science companies.

## About GVK BIO

GVK Biosciences (GVK BIO, [www.gvkbio.com](http://www.gvkbio.com)) is Asia's leading Discovery Research and Development organization. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. GVK BIO's discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO's diverse portfolio of more than 200 customers includes some of the world's largest pharmaceutical, biotechnology, agro, life science companies and leading academic institutions.

Regards

Team Corporate Marketing